{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T07:50:12Z","timestamp":1793346612678,"version":"4.5.0"},"reference-count":31,"publisher":"SAGE Publications","issue":"6","license":[{"start":{"date-parts":[[2021,11,2]],"date-time":"2021-11-02T00:00:00Z","timestamp":1635811200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JND"],"published-print":{"date-parts":[[2021,11,2]]},"abstract":"<jats:p>Background Eteplirsen received accelerated FDA approval for treatment of Duchenne muscular dystrophy (DMD) with mutations amenable to exon 51 skipping, based on demonstrated dystrophin production. Objective To report results from PROMOVI, a phase 3, multicenter, open-label study evaluating efficacy and safety of eteplirsen in a larger cohort. Methods Ambulatory patients aged 7\u201316 years, with confirmed mutations amenable to exon 51 skipping, received eteplirsen 30\u200amg\/kg\/week intravenously for 96 weeks. An untreated cohort with DMD not amenable to exon 51 skipping was also enrolled. Results 78\/79 eteplirsen-treated patients completed 96 weeks of treatment. 15\/30 untreated patients completed the study; this cohort was considered an inappropriate control group because of genotype-driven differences in clinical trajectory. At Week 96, eteplirsen-treated patients showed increased exon skipping (18.7-fold) and dystrophin protein (7-fold) versus baseline. Post-hoc comparisons with patients from eteplirsen phase 2 studies (4658-201\/202) and mutation-matched external natural history controls confirmed previous results, suggesting clinically notable attenuation of decline on the 6-minute walk test over 96 weeks (PROMOVI: \u201368.9\u200am; phase 2 studies: \u201367.3\u200am; external controls: \u2013133.8\u200am) and significant attenuation of percent predicted forced vital capacity annual decline (PROMOVI: \u20133.3%, phase 2 studies: \u20132.2%, external controls: \u20136.0%; p\u200a&lt;\u200a0.001). Adverse events were generally mild to moderate and unrelated to eteplirsen. Most frequent treatment-related adverse events were headache and vomiting; none led to treatment discontinuation. Conclusions This large, multicenter study contributes to the growing body of evidence for eteplirsen, confirming a positive treatment effect, favorable safety profile, and slowing of disease progression versus natural history.<\/jats:p>","DOI":"10.3233\/jnd-210643","type":"journal-article","created":{"date-parts":[[2021,6,8]],"date-time":"2021-06-08T17:31:47Z","timestamp":1623173507000},"page":"989-1001","source":"Crossref","is-referenced-by-count":113,"title":["Open-Label Evaluation of Eteplirsen in Patients with Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping: PROMOVI Trial"],"prefix":"10.1177","volume":"8","author":[{"given":"Craig M.","family":"McDonald","sequence":"first","affiliation":[{"name":"Departments of Physical Medicine & Rehabilitation and Pediatrics, University of California Davis Health System and School of Medicine, Sacramento, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of the the Italian DMD Telethon Registry Study Group, Leuven NMRC Registry Investigators, CINRG Duchenne Natural History Investigators, and PROMOVI Trial Clinical Investigators","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Perry B.","family":"Shieh","sequence":"additional","affiliation":[{"name":"Department of Neurology, University of California, Los Angeles, Los Angeles, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hoda Z.","family":"Abdel-Hamid","sequence":"additional","affiliation":[{"name":"UPMC Children\u2019s Hospital of Pittsburgh, Pittsburgh, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne M.","family":"Connolly","sequence":"additional","affiliation":[{"name":"Pediatrics, Center for Gene Therapy, Nationwide Children\u2019s Hospital, Columbus, OH, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Ciafaloni","sequence":"additional","affiliation":[{"name":"University of Rochester Medical Center, Rochester, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn R.","family":"Wagner","sequence":"additional","affiliation":[{"name":"Center for Genetic Muscle Disorders, Kennedy Krieger Institute, Baltimore, MD, USA"},{"name":"Departments of Neurology and Neuroscience, Johns Hopkins School of Medicine, Baltimore, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie","family":"Goemans","sequence":"additional","affiliation":[{"name":"Department of Pediatrics and Child Neurology, University Hospitals Leuven, Leuven, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugenio","family":"Mercuri","sequence":"additional","affiliation":[{"name":"Pediatric Neurology, Catholic University, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Navid","family":"Khan","sequence":"additional","affiliation":[{"name":"Sarepta Therapeutics, Inc., Cambridge, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erica","family":"Koenig","sequence":"additional","affiliation":[{"name":"Sarepta Therapeutics, Inc., Cambridge, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jyoti","family":"Malhotra","sequence":"additional","affiliation":[{"name":"Sarepta Therapeutics, Inc., Cambridge, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenfei","family":"Zhang","sequence":"additional","affiliation":[{"name":"Sarepta Therapeutics, Inc., Cambridge, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baoguang","family":"Han","sequence":"additional","affiliation":[{"name":"Sarepta Therapeutics, Inc., Cambridge, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerry R.","family":"Mendell","sequence":"additional","affiliation":[{"name":"Pediatrics, Center for Gene Therapy, Nationwide Children\u2019s Hospital, Columbus, OH, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","reference":[{"issue":"3","key":"10.3233\/JND-210643_ref1","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/S1474-4422(18)30024-3","article-title":"Diagnosis and management of Duchenne muscular dystrophy, part diagnosis, and neuromuscular, rehabilitation, endocrine, and gastrointestinal and nutritional management","volume":"17","author":"Birnkrant","year":"2018","journal-title":"Lancet Neurol"},{"issue":"1","key":"10.3233\/JND-210643_ref2","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1186\/s13023-020-01430-8","article-title":"Global epidemiology of Duchenne muscular dystrophy: an updated systematic review and meta-analysis","volume":"15","author":"Crisafulli","year":"2020","journal-title":"Orphanet J Rare Dis"},{"issue":"21","key":"10.3233\/JND-210643_ref3","doi-asserted-by":"publisher","first-page":"1886","DOI":"10.1212\/wnl.0000000000002147","article-title":"Histologic muscular history in steroid-treated and untreated patients with Duchenne dystrophy","volume":"85","author":"Peverelli","year":"2015","journal-title":"Neurology"},{"issue":"2","key":"10.3233\/JND-210643_ref4","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/s1474-4422(09)70272-8","article-title":"Diagnosis and management of Duchenne muscular dystrophy, part implementation of multidisciplinary care","volume":"9","author":"Bushby","year":"2010","journal-title":"Lancet Neurol"},{"issue":"1","key":"10.3233\/JND-210643_ref5","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/s1474-4422(09)70271-6","article-title":"Diagnosis and management of Duchenne muscular dystrophy, part diagnosis, and pharmacological and psychosocial management","volume":"9","author":"Bushby","year":"2010","journal-title":"Lancet Neurol"},{"issue":"3","key":"10.3233\/JND-210643_ref6","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1038\/mt.2008.287","article-title":"Design of phosphorodiamidate morpholino oligomers (PMOs) for the induction of exon skipping of the human DMD gene","volume":"17","author":"Popplewell","year":"2009","journal-title":"Mol Ther"},{"issue":"9791","key":"10.3233\/JND-210643_ref8","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/s0140-6736(11)60756-3","article-title":"Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation study","volume":"378","author":"Cirak","year":"2011","journal-title":"Lancet"},{"key":"10.3233\/JND-210643_ref9","doi-asserted-by":"publisher","first-page":"533","DOI":"10.2147\/dddt.S97635","article-title":"Eteplirsen in the treatment of Duchenne muscular dystrophy","volume":"11","author":"Lim","year":"2017","journal-title":"Drug Des Devel Ther"},{"issue":"3","key":"10.3233\/JND-210643_ref10","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1002\/humu.20918","article-title":"Theoretic applicability of antisense-mediated exon skipping for Duchenne muscular dystrophy mutations","volume":"30","author":"Aartsma-Rus","year":"2009","journal-title":"Hum Mutat"},{"issue":"4","key":"10.3233\/JND-210643_ref11","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1212\/wnl.0000000000002891","article-title":"DMD genotypes and loss of ambulation in the CINRG Duchenne Natural History Study","volume":"87","author":"Bello","year":"2016","journal-title":"Neurology"},{"issue":"6","key":"10.3233\/JND-210643_ref12","doi-asserted-by":"publisher","first-page":"e0218683","DOI":"10.1371\/journal.pone.0218683","article-title":"Long-term natural history data in Duchenne muscular dystrophy ambulant patients with mutations amenable to skip exons 44, 45, 51 and 53","volume":"14","author":"Brogna","year":"2019","journal-title":"PLoS One"},{"issue":"1","key":"10.3233\/JND-210643_ref13","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1111\/dmcn.12922","article-title":"Neurodevelopmental, emotional, and behavioural problems in Duchenne muscular dystrophy in relation to underlying dystrophin gene mutations","volume":"58","author":"Ricotti","year":"2016","journal-title":"Dev Med Child Neurol"},{"issue":"5","key":"10.3233\/JND-210643_ref14","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1002\/acn3.51046","article-title":"Genetic modifiers of respiratory function in Duchenne muscular dystrophy","volume":"7","author":"Bello","year":"2020","journal-title":"Ann Clin Transl Neurol"},{"issue":"2","key":"10.3233\/JND-210643_ref15","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1002\/ana.24555","article-title":"Longitudinal effect of eteplirsen versus historical control on ambulation in Duchenne muscular dystrophy","volume":"79","author":"Mendell","year":"2016","journal-title":"Ann Neurol"},{"issue":"5","key":"10.3233\/JND-210643_ref16","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1002\/ana.23982","article-title":"Eteplirsen for the treatment of Duchenne muscular dystrophy","volume":"74","author":"Mendell","year":"2013","journal-title":"Ann Neurol"},{"issue":"1","key":"10.3233\/JND-210643_ref17","doi-asserted-by":"publisher","first-page":"47","DOI":"10.3233\/jnd-170272","article-title":"Long-term pulmonary function in Duchenne muscular dystrophy: comparison of eteplirsen-treated patients to natural history","volume":"5","author":"Kinane","year":"2018","journal-title":"J Neuromuscul Dis"},{"issue":"26","key":"10.3233\/JND-210643_ref18","doi-asserted-by":"publisher","first-page":"e15858","DOI":"10.1097\/md.0000000000015858","article-title":"Long-term treatment with eteplirsen in nonambulatory patients with Duchenne muscular dystrophy","volume":"98","author":"Alfano","year":"2019","journal-title":"Medicine (Baltimore)"},{"key":"10.3233\/JND-210643_ref19","doi-asserted-by":"publisher","DOI":"10.3233\/jnd-200548"},{"issue":"1","key":"10.3233\/JND-210643_ref20","first-page":"45","article-title":"ICH Harmonized Tripartite Guideline: Guideline for Good Clinical Practice","volume":"47","author":"International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use","year":"2001","journal-title":"J Postgrad Med"},{"issue":"4","key":"10.3233\/JND-210643_ref21","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1002\/mus.21544","article-title":"The 6-minute walk test as a new outcome measure in Duchenne muscular dystrophy","volume":"41","author":"McDonald","year":"2010","journal-title":"Muscle Nerve"},{"issue":"2","key":"10.3233\/JND-210643_ref22","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1002\/pri.520","article-title":"Development of a functional assessment scale for ambulatory boys with Duchenne muscular dystrophy","volume":"17","author":"Scott","year":"2012","journal-title":"Physiother Res Int"},{"issue":"1","key":"10.3233\/JND-210643_ref23","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1164\/ajrccm.159.1.9712108","article-title":"Spirometric reference values from a sample of the general U.S. population.","volume":"159","author":"Hankinson","year":"1999","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"10.3233\/JND-210643_ref25","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1186\/s13023-018-0918-z","article-title":"The Italian neuromuscular registry: a coordinated platform where patient organizations and clinicians collaborate for data collection and multiple usage","volume":"13","author":"Ambrosini","year":"2018","journal-title":"Orphanet J Rare Dis"},{"issue":"10","key":"10.3233\/JND-210643_ref26","doi-asserted-by":"publisher","first-page":"e108205","DOI":"10.1371\/journal.pone.0108205","article-title":"Long term natural history data in ambulant boys with Duchenne muscular dystrophy: 36-month changes","volume":"9","author":"Pane","year":"1082","journal-title":"PLoS One"},{"issue":"2","key":"10.3233\/JND-210643_ref27","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/s13760-014-0320-0","article-title":"Early stages of building a rare disease registry, methods and data from the Belgian Neuromuscular Disease Registry (BNMDR)","volume":"115","author":"Roy","year":"2015","journal-title":"Acta Neurol Belg"},{"issue":"2","key":"10.3233\/JND-210643_ref28","doi-asserted-by":"publisher","first-page":"213","DOI":"10.3233\/JND-180351","article-title":"Eteplirsen treatment attenuates respiratory decline in ambulatory and non-ambulatory patients with Duchenne muscular dystrophy","volume":"6","author":"Khan","year":"2019","journal-title":"J Neuromuscul Dis"},{"issue":"6","key":"10.3233\/JND-210643_ref29","doi-asserted-by":"publisher","first-page":"2484","DOI":"10.1096\/fj.12-224170","article-title":"Low dystrophin levels increase survival and improve muscle pathology and function in dystrophin\/utrophin double-knockout mice","volume":"27","author":"van Putten","year":"2013","journal-title":"FASEB J"},{"issue":"1","key":"10.3233\/JND-210643_ref30","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1001\/jamaneurol.2013.4908","article-title":"Biochemical characterization of patients with in-frame or out-of-frame DMD deletions pertinent to exon 44 or 45 skipping","volume":"71","author":"Anthony","year":"2014","journal-title":"JAMA Neurol"},{"key":"10.3233\/JND-210643_ref31","doi-asserted-by":"publisher","DOI":"10.1002\/ana.25951"},{"issue":"2","key":"10.3233\/JND-210643_ref32","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.nmd.2017.11.007","article-title":"Low-level dystrophin expression attenuating the dystrophinopathy phenotype","volume":"28","author":"Waldrop","year":"2018","journal-title":"Neuromuscul Disord"},{"issue":"10","key":"10.3233\/JND-210643_ref33","doi-asserted-by":"publisher","first-page":"1953","DOI":"10.1007\/s00467-020-04587-3","article-title":"Kidney involvement and associated risk factors in children with Duchenne muscular dystrophy","volume":"35","author":"Kutluk","year":"2020","journal-title":"Pediatr Nephrol"}],"container-title":["Journal of Neuromuscular Diseases"],"original-title":[],"link":[{"URL":"https:\/\/content.iospress.com\/download?id=10.3233\/JND-210643","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T23:49:47Z","timestamp":1777506587000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/full\/10.3233\/JND-210643"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,2]]},"references-count":31,"journal-issue":{"issue":"6"},"URL":"https:\/\/doi.org\/10.3233\/jnd-210643","relation":{},"ISSN":["2214-3599","2214-3602"],"issn-type":[{"value":"2214-3599","type":"print"},{"value":"2214-3602","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,2]]}}}